Triptorelin extended release - Xbrane

Drug Profile

Triptorelin extended release - Xbrane

Alternative Names: Microrelin; Spherotide

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Primm srl
  • Developer Pooyesh Darou; Xbrane
  • Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Endometriosis; Prostate cancer; Uterine leiomyoma
  • Clinical Phase Unknown Breast cancer; Precocious puberty

Most Recent Events

  • 06 Feb 2018 Triptorelin extended release licensed to China Resource Pharmaceutical Group in China
  • 21 Dec 2017 Xbrane Biopharma expects to sign a final agreement with potential partners regarding out-licensing of triptorelin in China during the first quarter of 2018
  • 19 Dec 2017 Triptorelin extended release market licensed to BL&H in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top